TCL Archive FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate. May 28, 2004
TCL Archive Shortage Of Patients In Right Place, Time Develops As Major Problem For Investigators May 3, 1974
TCL Archive Bristol-Myers Squibb Co. has agreed to pay $450 million to settle class action suits from shareholders and separate civil claims by the Securities and Exchange Commission. The settlements stem from Bristol’s practice of building up wholesalers’ inventories and diverting operating income to enhance dividends. August 6, 2004
